An Investigation to Identify Risk Factors for the Development of Acneiform Eruptions in Patients on Epidermal Growth Factor Receptor Inhibitors

一项旨在确定使用表皮生长因子受体抑制剂的患者发生痤疮样皮疹的危险因素的调查

• 批准号: 466972
• 负责人: Bierbrier Rachel M
• 金额: $ 1.27万
• 依托单位: McGill University
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-12-01 至 2022-12-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=466972&lang=en
• 关键词: Acne Vulgaris; Acneiform Eruption/Rash; Epidermal Growth Factor Receptor Inhibitors; Gastrointestinal Cancer; Head And Neck Cancer; Non Small Cell Lung Cancer; Oncology; Skin Adverse Events; Targeted Therapy; Tyrosine Kinase Inhibitors

Newer targeted cancer therapies, including epidermal growth factor receptor inhibitors, have fewer systemic side effects than older chemotherapy but cause a near-universal acneiform rash. This rash looks very similar to acne - it is pimples and red bumps

较新的靶向癌症治疗，包括表皮生长因子受体抑制剂，比旧的化疗具有更少的全身副作用，但会导致几乎普遍的痤疮样皮疹。这种皮疹看起来很像痤疮-这是丘疹和红色肿块